Search Results
Sep 15, 2026, 00:05 ET Seattle Children's ranks among nation's top 10 children's hospitals for third straight year
placing in the nation's top 10: Cancer Diabetes & Endocrinology Nephrology Pulmonology & Lung Surgery For the 2026-2027 rankings, U.S. News, together with RTI International, a North Carolina-based research firm,
More news about: Seattle Children's
Sep 15, 2026, 00:01 ET Lucile Packard Children's Hospital Stanford Ranks Among Top Children's Hospitals by U.S. News & World Report and Ties for Best in Northern California
Neonatology and NephrologyTop 10 nationally in four specialties: Neonatology, Nephrology, Neurology & Neurosurgery, and Pulmonology & Lung SurgeryPALO ALTO, Calif., Sept. 15, 2026 /PRNewswire/ --
More news about: Stanford Medicine Children's Health and Lucile Packard Children's Hospital Stanford
Sep 15, 2026, 00:01 ET Texas Children's Named a Best Children's Hospital and is Number One in Texas Again for 18th Consecutive Year
SurgeryNo. 1: Diabetes & EndocrinologyNo. 2: Nephrology (Kidney disorders)No. 2: Pulmonology & Lung SurgeryNo. 2: UrologyNo. 3: Neurology & NeurosurgeryNo. 5: Gastroenterology & GI SurgeryNo.
More news about: Texas Children's Hospital
Sep 14, 2026, 23:00 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
survival and overall response rate.9About non-small cell lung cancerWorldwide, lung cancer is one of the most common cancers, with non-small cell lung cancer (NSCLC) making up 80 to 85 percent of all lung cancer cases.10,11 The main subtypes of NSCLC are adenocarcinoma,
More news about: Johnson & Johnson
Sep 14, 2026, 12:00 ET Piezo Direct Announces the World's Most Advanced Mesh-Based Piezo Atomizer for Nebulizing and Vaping Applications
of resolidified metal around the rim. We cannot predict whether a piece will break loose, or when, or which piece. If one ever does and it reaches a lung, that is a disaster. We spent years and a great deal of money making that volcano go away."— Li Hsu, CEO, Piezo DirectHolding
More news about: Piezo Direct
Sep 14, 2026, 11:29 ET Zipalertinib Plus Chemotherapy Significantly Extends Progression-Free Survival in First-Line EGFR Exon 20 Insertion-Positive NSCLC
receiving first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, according to results presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).
More news about: International Association for the Study of Lung Cancer
Sep 14, 2026, 10:31 ET Bispecifics Market to Gain Momentum During the Forecast Period (2026-2036) with Expanding Pipeline and Increasing Therapeutic Adoption | DelveInsight
such as Acute Lymphocytic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma, Multiple Myeloma, Non-small-cell Lung Cancer (NSCLC), Small-cell Lung Cancer (SCLC), Biliary Tract Cancer (BTC), Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), and others. The selected indications
More news about: DelveInsight Business Research, LLP
Sep 14, 2026, 10:25 ET Phase 3 DESTINY-Lung04 Trial Shows First-Line Trastuzumab Deruxtecan Significantly Improves Progression-Free Survival in HER2-Mutant NSCLC
advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC), according to primary results from the Phase 3 DESTINY-Lung04 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).
More news about: International Association for the Study of Lung Cancer
Sep 14, 2026, 09:22 ET Eight-Year ADAURA Update Shows Sustained Overall Survival Benefit With Adjuvant Osimertinib in Resected EGFR-Mutated NSCLC
patients with completely resected, EGFR-mutated stage IB-IIIA non-small cell lung cancer (NSCLC). The findings were presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).
More news about: International Association for the Study of Lung Cancer
Sep 14, 2026, 09:00 ET FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA®
patients with previously treated small-cell lung cancer. N Engl J Med. 2023;389(22):2063-2075. doi:10.1056/NEJMoa2307980/.Rojo F, Corassa M, Mavroudis D, et al. International real-world study of DLL3 expression in patients with small cell lung cancer. Lung Cancer. 2020;147:237-243. doi:10.1016/j.lungcan.2020.07.026.
More news about: Amgen
Sep 14, 2026, 08:30 ET Bitmine Immersion Technologies (mã: BMNR) Thông Báo Lượng ETH Nắm Giữ Đạt 5,96 Triệu Token, Tổng Số Tiền Mã Hóa và Tiền Mặt Nắm Giữ Đạt 15,8 Tỷ USD
liên kết tại đây) cho tháng 7 năm 2026. Tiêu đề của Thông Điệp này là "ETH chính là liều thuốc giải cho Thung Lũng Kỳ Lạ của Sự Giàu Có".Vào đầu năm 2026, Bitmine đã ra mắt MAVAN (Made in American VAlidator Network) – nền tảng staking chuyên biệt dành cho
More news about: Bitmine Immersion Technologies, Inc.
Sep 14, 2026, 08:18 ET Zidesamtinib Demonstrates 93% Response Rate in TKI-Naive Patients With Advanced ROS1-Positive NSCLC
or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who had not previously received a tyrosine kinase inhibitor (TKI). The findings were presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).
More news about: International Association for the Study of Lung Cancer
Sep 14, 2026, 07:14 ET In the PAPILLON Study, First-Line Amivantamab-Chemotherapy Demonstrates the Longest Overall Survival Reported for EGFR Exon 20 Insertion-Positive Advanced NSCLC
with previously untreated advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (Ex20ins) mutations. The findings were presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).
More news about: International Association for the Study of Lung Cancer
Sep 14, 2026, 06:00 ET Veteran Health Tech Leader Jim Longley Joins the Outcomes4Me Executive Team to Accelerate Growth and Support Mission of Empowering Patients with Cancer
National Comprehensive Cancer Network® (NCCN®) updates into the Outcomes4Me platform, spanning bladder cancer, breast cancer, kidney cancer, non-small cell lung cancer, and prostate cancer. These NCCN Guidelines® updates ensure patients using the Outcomes4Me platform have access to the latest recommended
More news about: Outcomes4Me Inc.
Sep 14, 2026, 02:18 ET Results from Phase III Study of Trastuzumab Botidotin versus T-DM1 in HER2-Positive Breast Cancer Published in JCO
the risk of death (Figure D).In terms of safety, patients in the trastuzumab botidotin group had a low incidence of interstitial lung disease (ILD), and the incidences of hematologic, hepatic, and gastrointestinal toxicities were notably lower than those in the T-DM1 group, along with
More news about: Kelun-Biotech
Sep 13, 2026, 21:45 ET Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer
patients in the control arm.13About non-small cell lung cancerWorldwide, lung cancer is one of the most common cancers, with non-small cell lung cancer (NSCLC) making up 80 to 85 percent of all lung cancer cases.14,15 The main subtypes of NSCLC are adenocarcinoma,
More news about: Johnson & Johnson
Sep 13, 2026, 21:30 ET Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026
ADC target in patients with pretreated, EGFR wild-type non-small cell lung cancer (NSCLC). The data will be presented at the IASLC 2026 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer, taking place September 12-15, 2026, in Seoul, Republic of Korea.
More news about: Whitehawk Therapeutics, Inc.
Sep 13, 2026, 08:57 ET Phase III TAISHAN-302 Trial Shows Tam-Peli Significantly Improves Survival in Relapsed Small-Cell Lung Cancer
response rate compared with topotecan in patients with relapsed small-cell lung cancer (SCLC). The findings were presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).
More news about: International Association for the Study of Lung Cancer
Sep 13, 2026, 08:54 ET Phase III MAVERICK Trial Supports Brain MRI Surveillance Alone as Standard of Care for Small-Cell Lung Cancer
in patients with small-cell lung cancer (SCLC). The findings support MRI surveillance alone as the standard of care for patients with SCLC, according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).
More news about: International Association for the Study of Lung Cancer
Sep 13, 2026, 07:50 ET Sacituzumab Govitecan Plus Pembrolizumab Does Not Meet Primary Endpoints in First-Line PD-L1-High Metastatic NSCLC
metastatic non-small cell lung cancer (NSCLC) and PD-L1 tumor proportion score (TPS) of 50% or greater, according to primary results from the Phase 3 EVOKE-03/KEYNOTE-D46 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).
More news about: International Association for the Study of Lung Cancer
Sep 13, 2026, 07:46 ET Phase III ARTEMIS-008 Trial Shows Risvutatug Rezetecan Significantly Improves Overall Survival in Relapsed Small-Cell Lung Cancer
IASLCThe International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 10,000 lung cancer specialists across all disciplines in over
More news about: International Association for the Study of Lung Cancer
Sep 13, 2026, 02:59 ET Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026
double-blind, multicenter, registrational Phase III HARMONi-2 study (AK112-303) at the 2026 World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC). The study evaluated the company's first-in-class next-generation immuno-oncology therapy, ivonescimab,
More news about: Akeso, Inc.
Sep 12, 2026, 07:19 ET International Association for the Study of Lung Cancer Launches Complimentary IASLC Full Membership for Eligible Countries to Expand Worldwide Participation in Thoracic Oncology
IASLCThe International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 11,000 lung cancer specialists across all disciplines in over
More news about: International Association for the Study of Lung Cancer
Sep 12, 2026, 05:15 ET SystImmune, Inc. to Present New Global Data on Iza-bren (izalontamab brengitecan) in EGFR-mutated Non-Small Cell Lung Cancer at WCLC Congress 2026
bispecific antibody drug conjugate (ADC), will be presented in an oral presentation at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC) taking place September 12 – 15 in Seoul, South Korea. Iza-bren is being developed under a license and collaboration
More news about: SystImmune, Inc.
Sep 11, 2026, 09:00 ET 2026 Wealth Management Industry Awards Celebrate Record-Breaking Year and the Innovators Advancing Financial Advice
industry participant and former Wealthies judge, Powell spent two decades as one of wealth management's most beloved voices. After receiving a stage 4 lung cancer diagnosis, she shared her journey publicly and turned an extraordinarily difficult chapter into a source of strength for others. The award honors
More news about: Wealth Management